Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR Combined With Sintilimab in Early Inoperable sMPLC
NCT04840758Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in multiple primary lung cancer (MPLC), sponsored by First Affiliated Hospital of Xiamen University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
multiple primary lung cancer (MPLC)
Beyond the preview
Go deeper on NCT04840758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840758.